Publication Topic

Sacks NC, Ash AS, Ghosh K, Rosen AK, Wong JB, Cutler DM, Rosen AB. 2015. Recent national trends in acute myocardial infarction hospitalizations in Medicare: Shrinking declines and growing disparities [Letter to the Editor]. Epidemiology 26(4):e46–47.

Sacks NC, Burgess JF, Cabral HJ, McDonnell ME, Pizer SD. 2015. The effects of cost sharing on adherence to medications prescribed for concurrent use: Do definitions matter? J Manag Care Pharmacy 21(8):678–687.

Sacks NC, Ash AS, Ghosh K, Rosen AK, Wong JB, Rosen AB. 2015. Trends in acute myocardial infarction hospitalizations: Are we seeing the whole picture? Am Heart J 170(6):1211-1219; doi: 10.1016/j.ahj.2015.09.009.

Jensen IS, Bay C, Cyr PL. Estimating the impact of combining cangrelor and bivalirudin to a U.S. hospital performing PCI procedures. ISPOR 18^th Annual International Meeting, New Montreal Quebec, 2014.

Pinto DS, Nicholson G, Harrington RA, Cyr PL, Bhatt DL. CHAMPION PHOENIX Study economic results: Direct hospitalization costs of patients receiving clopidogrel or cangralor during percutaneous coronary intervention. American Heart Association QCOR conference, Baltimore, MD, 2014.

Jensen IS, Wu C, Bay CB, Cyr PL. Estimating the clinical value of cangrelor in patients undergoing PCI. International Academy of Cardiology, 19th World Congress on Heart Disease, Boston, MA, 2014.

Wu C, Fortier K, Fan WJ, LePensse K, Bay CB, Cyr PL, Jensen IS. A U.S. hospital budget impact model for oritivancin in ABSSSI patients with risk of MRSA infections. ISPOR 16^th Annual European Congress, Amsterdam, Netherlands, 2014.

Bay C, Cyr PL, Jensen IS. Estimating the value of cangrelor from eliminating preloading in coronary artery bypass graft (CABG) patients. ISPOR 16th Annual European Congress, Amsterdam, Netherlands, 2014.

Olchanski N, McInnis-Myers M, Halseth M, Cyr PL, Bockstedt L, Goss TF, Howland RH. 2013. The economic burden of treatment-resistant depression. Clin Ther 35(4):512-522; doi: 10.1016/j.clinthera.2012.09.001.

Sacks NC. 2013. Avoidable costs in U.S. healthcare: The $200 billion opportunity from using medicines more responsibly. IMS Health, June.